



# Improved survival after one course of perioperative chemotherapy in early breast cancer patients: long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854

J.A. van der Hage<sup>a,b</sup>, C.J.H. van de Velde<sup>b,\*</sup>, J.-P. Julien<sup>c</sup>, J.-L. Floiras<sup>d</sup>, T. Delozier<sup>e</sup>,  
C. Vandervelden<sup>a</sup>, L. Duchateau<sup>a</sup> and cooperating investigators

<sup>a</sup>European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium

<sup>b</sup>Department of Surgery, D6-43, Leiden University Medical Center, PO Box 9600 2300 RC Leiden, The Netherlands

<sup>c</sup>Centre Henri Becquerel, Department of Surgery, Rouen, France

<sup>d</sup>Centre René Huguenin, Department of Radiation Oncology, St Cloud, France

<sup>e</sup>Centre Régional François Baclesse, Caen, France

Received 30 January 2001; received in revised form 31 May 2001; accepted 13 August 2001

## Abstract

The aim of this study was to examine whether one course of perioperative polychemotherapy yields better results in terms of survival, progression-free survival (PFS) and locoregional control than surgery alone in early stage breast cancer. From 1986 to 1991, 2795 patients with stage I/II breast cancer were randomised to receive either one perioperative course of an anthracycline-containing chemotherapeutic regimen within 36 h after surgery or surgery alone. Patients were followed-up for overall survival, PFS and locoregional recurrence. The median follow-up period at time of the analysis was 11 years. PFS and locoregional control were significantly better ( $P=0.025$  and  $P=0.004$ , respectively) in the perioperative chemotherapy arm. Node-negative patients seemed to benefit most from the perioperative FAC. Patients who received perioperative chemotherapy and locoregional therapy alone had significantly better overall survival rates than patients who received locoregional therapy alone ( $P=0.004$ ). Patients who received additional systemic therapy did not seem to benefit from one course of perioperative chemotherapy ( $P=0.65$ ). One course of perioperative polychemotherapy does improve PFS and locoregional control in early stage breast cancers. This effect is still present after 11 years of follow-up. © 2001 Published by Elsevier Science Ltd. All rights reserved.

**Keywords:** Breast cancer; Perioperative chemotherapy; FAC

## 1. Introduction

Systemic adjuvant therapy has been shown to improve both disease-free survival and overall survival in breast cancer patients [1]. Over the past three decades, many investigators have studied the benefits of adjuvant chemotherapy in breast cancer. However, the significance of the timing of administration of chemotherapy in relation to locoregional treatment is still a matter of debate.

Experimental studies, as well as mathematical hypotheses [2–6], have demonstrated that early timing of chemotherapy may be more effective than standard postoperative administration of chemotherapy.

Several randomised trials studying the effect of the administration of one dose of chemotherapy immediately after surgery with or without subsequent prolonged chemotherapy demonstrated better disease-free or relapse-free survival rates using this therapeutic regimen [7–9]. In the European Organization for Research and Treatment of Cancer (EORTC) trial 10854, of which preliminary results have been published previously, a similar effect was observed at a median follow-up time of 41 months [10]. In this report, we will

\* Corresponding author. Tel.: +31-71-526-2309; fax +31-71-526-6750.

E-mail address: velde@lumc.nl (C.J.H. van de Velde).

focus on the effect of perioperative chemotherapy after long-term follow-up.

## 2. Patients and methods

### 2.1. Patient characteristics

Eligibility requirements, randomisation procedures, surgical and radiation techniques used, characteristics of patients and tumours, and the distribution of patients among the treatment groups have been published previously [10]. In brief, eligible patients had primary operable breast cancer, T1-3, N0-2, M0, and had to be younger than 70 years of age at the time of randomisation. Exclusion criteria were bilateral breast cancer, previous treatment for breast cancer and previous systemic treatment for other cancers, distant metastases, and a poor World Health Organization (WHO) performance ( $> 2$ ). Patients were randomised to either receive one course of perioperative chemotherapy within 36 h after surgery or surgery alone. Patient characteristics are shown in Table 1. Patients who were younger than

or equal to 50 years of age at the time of diagnosis were classified as premenopausal. Patients older than 50 years were considered postmenopausal. Tumour oestrogen receptor status (ER) was measured using a biochemical assay according to the best method locally available at every institution. A value of  $\geq 10$  fmol ER per mg protein was considered positive and a value of 0–9 fmol ER per mg protein was considered negative [11]. No information on the progesterone receptor status was collected. In the subgroup of node-negative premenopausal patients, ER status was also measured by immunohistochemistry in a central pathology review.

### 2.2. Treatment

Patients were treated with either (modified) radical mastectomy or breast-conserving surgery. Perioperative chemotherapy consisted of one single course of 50 mg/m<sup>2</sup> doxorubicin, 600 mg/m<sup>2</sup> 5-fluorouracil, and 600 mg/m<sup>2</sup> cyclophosphamide (FAC), administered intravenously (i.v.) within 36 h after surgery. Axillary lymph node-positive premenopausal patients in the perioperative chemotherapy group were recommended to receive an extra five cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Node-positive patients, younger than 50 years, who did not receive perioperative chemotherapy, were advised to have one conventional course of FAC followed by five cycles of CMF after surgery. Adjuvant hormonal therapy at the time was not routinely given in the management of breast cancer and the decision to give tamoxifen was therefore left to the discretion of the respective investigators. Radiotherapy was given in both arms. Postoperative radiation had to be started 6 weeks after surgery and was given in all cases in which surgery was considered not to be radical. A detailed description concerning the administration of radiotherapy was given previously [10].

### 2.3. Statistical considerations

The primary endpoint of the EORTC 10854 trial is overall survival. Secondary endpoints are progression-free survival (PFS) and locoregional recurrence as the first event. PFS was defined as the time between the date of randomisation and the date of relapse (including secondary primary tumours and contralateral breast cancers) or death, whichever came first. A locoregional recurrence was defined as any recurrence in the breast or axilla. Only recurrences which occurred before the diagnosis of a distant metastasis and/or a new primary tumour were regarded as a locoregional recurrence as the first event and added to the analysis.

Statistical calculations were performed using the 'intent-to-treat principle'. This means that all data are used in the statistical calculations, regardless of the fact

Table 1  
Patient characteristics; all patients ( $n = 2793$ )

	Perioperative chemotherapy $n = 1398$	Control $n = 1395$
	$n$ (%)	$n$ (%)
Age (years)		
≤ 50	557 (40)	560 (40)
> 50	841 (60)	835 (60)
Nodal status (pathological)		
Negative	741 (53)	728 (52)
Positive	644 (46)	661 (47)
Missing data	13 (1)	6 (0.5)
Tumour size (clinical)		
≤ 2 cm	407 (29)	416 (30)
> 2 cm	969 (69)	954 (68)
Missing data	22 (2)	25 (2)
ER status		
ER +	910 (65)	909 (65)
ER –	324 (23)	347 (25)
Missing data	164 (12)	139 (10)
Type of surgery		
BCS <sup>a</sup>	773 (55)	770 (55)
Mastectomy	616 (44)	618 (44)
Missing data	9 (1)	7 (1)
Radiotherapy		
Yes	1082 (77)	1063 (76)
No	316 (23)	332 (24)
Additional systemic therapy		
Yes	606 (43)	592 (42)
No	756 (54)	776 (56)
Missing data	36 (3)	27 (2)

<sup>a</sup> Breast-conserving surgery. ER, oestrogen receptor.

whether a patient was eligible or not. PFS and overall survival curves, as well as locoregional recurrence rates, were estimated using the Kaplan–Meier method [12] and log-rank tests for the comparison of treatment effects were also used [13]. Cox proportional-hazard regression models [14] were used to estimate hazard ratios (HR) with their 95% confidence interval (CI). All tests were two-sided.

### 3. Results

#### 3.1. Main analysis

From May 1986 to March 1991, 2795 patients were enrolled from 16 institutions from nine different countries onto this trial (Appendix). 41 patients were ineligible. 2793 patients were included in the analysis. 2 patients, of whom information concerning randomisation was missing, were excluded from the analysis (Fig. 1).

After a median follow-up of 11 years, overall survival (71% versus 74%) was not significantly different between the two treatment groups (HR = 0.9; 95% CI: 0.78–1.37;  $P=0.14$ ) (Fig. 2). However, PFS rates (53% versus 59%) are significantly different in favour of the perioperative chemotherapy group (HR = 0.88; 95% CI: 0.78–0.98;  $P=0.025$ ) (Fig. 3). In line with the PFS results, locoregional control (86% versus 91%) was sig-

nificantly different also in favour of the study-arm; (HR = 0.69; 95% CI: 0.54–0.89;  $P=0.004$ ) (Fig. 4).

#### 3.2. Subgroup analyses

To study the effect of perioperative chemotherapy in the specified groups of patients, subgroup analyses were carried out. However, one must interpret the outcome of these analyses with caution, as these were not pre-planned analyses and are therefore only to be regarded as exploratory analyses.

##### 3.2.1. Node-negative patients

1467 patients without axillary lymph node metastases were included in the trial. Node-negative patients in the study-arm did not have a significant better overall survival (HR = 0.89; 95% CI: 0.70–1.13;  $P=0.33$ ) after perioperative FAC. However, a significant effect of perioperative FAC was observed on the PFS rate (HR = 0.83; 95% CI: 0.70–0.99;  $P=0.035$ ). In addition, perioperative chemotherapy did have a profound effect on locoregional control in this subgroup, resulting in a significant difference in the locoregional control rates (HR = 0.67; 95% CI: 0.48–0.93;  $P=0.018$ ) in favour of the study-arm.

##### 3.2.2. Patients with T1 tumours

Patients with small tumours who received perioperative FAC did not benefit significantly in terms of overall survival (HR = 0.86; 95% CI: 0.62–1.18;  $P=0.34$ ) and PFS (HR = 0.92; 95% CI: 0.73–1.17;  $P=0.50$ ). However, perioperative chemotherapy had a marginally favourable effect on locoregional control (HR = 0.64; 95% CI: 0.42–0.99;  $P=0.047$ ).

##### 3.2.3. Premenopausal patients

Premenopausal patients have been established as the patients that benefit the most from adjuvant chemotherapy for breast cancer. Patients younger than or equal to 50 years of age at the time of diagnosis were deemed to be premenopausal patients in this study. Perioperative chemotherapy did not yield better overall survival rates (HR = 0.91; 95% CI: 0.72–1.15;  $P=0.43$ ) or PFS rates (HR = 0.87; 95% CI: 0.73–1.05;  $P=0.15$ ) in this subgroup. Moreover, the administration of one course of perioperative FAC did not result in better locoregional control rates (HR = 0.75; 95% CI: 0.53–1.05;  $P=0.096$ ).

##### 3.2.4. Timing of administration

We presumed that if timing influences treatment efficiency, this effect could only be demonstrated in patients who received extra adjuvant systemic therapy.

To study the ‘timing-effect’ of one course of perioperative FAC, we therefore selected all patients who received prolonged adjuvant systemic treatment. In




Fig. 1. Flow chart of the progress of patients through the trial (adapted from Ref. [23]).




Fig. 2. Overall survival. O, observed; N, numbers; Periop, perioperative.




Fig. 3. Progression-free survival. O, observed; N, numbers; Periop, perioperative.




Fig. 4. Locoregional recurrence as the first event. O, observed; N, numbers; Periop, perioperative.

total, 1198 patients were included in the ‘timing’ analysis, but no effect of timing was found on overall survival (HR = 0.65; 95% CI: 0.78–1.17;  $P = 0.65$ ) or PFS (HR = 0.94; 95% CI: 0.80–1.12;  $P = 0.50$ ), respectively. In addition, no effect of timing was found on locoregional control (HR = 0.88; 95% CI: 0.59–1.31;  $P = 0.52$ ).

### 3.2.5. Perioperative FAC as the sole systemic therapy

To test the absolute effect of one perioperative course of FAC, we compared the data of the patients in the control group who did not receive adjuvant systemic treatment with the patients who received perioperative chemotherapy alone in the study-arm. Patient characteristics are listed in Table 2. In this subset, which consisted of 1532 patients, a significant difference in favour of the perioperative chemotherapy group was shown in terms of overall survival (HR = 0.80; 95% CI: 0.64–0.98;  $P = 0.035$ ) and PFS (HR = 0.79; 95% CI: 0.67–0.93;  $P = 0.004$ ) (Figs. 5 and 6). Locoregional control was also significantly better in the study-arm (HR = 0.60; 95% CI: 0.43–0.83;  $P = 0.0023$ ) (Fig. 7).

### 3.2.6. Type of surgery

Perioperative chemotherapy did not have a significant effect on overall survival when patients were compared according to type of surgery (data not shown).

Interestingly, perioperative chemotherapy has a significant impact on PFS (HR = 0.84; 95% CI: 0.72–0.98;

Table 2

Patient characteristics; patients treated with one course of perioperative FAC and no further systemic therapy versus patients treated with locoregional therapy alone

	1 × perioperative FAC <i>n</i> = 756	Control <i>n</i> = 776
	<i>n</i> (%)	<i>n</i> (%)
Age (years)		
≤ 50	319 (42)	329 (42)
> 50	437 (58)	447 (58)
Nodal status (pathological)		
Negative	666 (90)	651 (86)
Positive	71 (10)	104 (14)
Missing data	19 (3)	21 (3)
Tumour size (clinical)		
< 2 cm	266 (36)	274 (36)
> 2 cm	480 (64)	488 (64)
Missing data	10 (1.5)	14 (2)
ER status		
ER +	477 (63)	478 (62)
ER –	188 (25)	207 (27)
Missing data	91 (12)	91 (12)
Type of surgery		
BCS	494 (65)	490 (63)
Mastectomy	259 (34)	283 (36)
Missing data	3 (0.5)	3 (0.5)

BCS, breast conserving surgery; ER, oestrogen receptor; FAC, doxorubicin, 5-fluorouracil and cyclophosphamide.




Fig. 5. Overall survival in patients with one course of perioperative FAC and no further systemic therapy versus patients treated with locoregional therapy alone. FAC, doxorubicin, 5-fluorouracil and cyclophosphamide; O, observed; N, numbers; Periop, perioperative.




Fig. 6. Progression-free survival in patients with one course of perioperative FAC and no further systemic therapy versus patients treated with locoregional therapy alone. O, observed; N, numbers; Periop, perioperative; FAC, doxorubicin, 5-fluorouracil and cyclophosphamide.




Fig. 7. Locoregional recurrence in patients with one course of perioperative FAC and no further systemic therapy versus patients treated with locoregional therapy alone. O, observed; N, numbers; Periop, perioperative; FAC, doxorubicin, 5-fluorouracil and cyclophosphamide.

$P=0.031$ ) and locoregional control (HR=0.71; 95% CI: 0.52–0.97;  $P=0.029$ ) in patients who underwent breast-conserving surgery, but not in patients who underwent mastectomy (HR=0.92; 95% CI: 0.78–1.08;  $P=0.30$  and HR=0.67; 95% CI: 0.43–1.04;  $P=0.074$ , respectively).

3.2.7. ER-status

ER-status was known in 89% of the patients. 65% was ER-positive, 24% were ER-negative. In the ER-positive population, patients who received perioperative chemotherapy had a marginally significant better locoregional control rates (HR=0.71; 95% CI: 0.52–0.98;  $P=0.04$ ). Perioperative chemotherapy did not have a significant effect on overall survival and PFS in ER-positive patients. In ER-negative patients, locoregional control as well as PFS or overall survival rates were not significantly altered by perioperative chemotherapy.

4. Discussion

This trial was set up primarily to study whether one course of chemotherapy given directly after surgery would yield better results in terms of prognosis than surgery alone in early stage breast cancer patients. As demonstrated in the main analyses, our results firmly demonstrate that perioperative chemotherapy after surgery leads to better locoregional control than surgery

alone. We also showed that one course of perioperative FAC significantly improves progression-free survival rates.

Moreover, in a subset of patients who received locoregional treatment alone, one course perioperative FAC resulted in significant higher survival rates for those given perioperative chemotherapy. However, when patients who also received prolonged courses of chemotherapy or patients who received hormonal therapy were studied, no significant effect of perioperative administration of FAC could be shown.

Ever since chemotherapy became part of the therapeutic strategy against breast cancer, timing has been a matter of discussion. Several trials have studied early administration of (poly) chemotherapy after surgery [7–9,15–17]. These trials and their overall results are listed in Table 3. To date, however, no evidence of a significant effect of early timing of chemotherapy after primary tumour removal on treatment outcome has been demonstrated.

Since EORTC trial 10854 was initiated in 1986, the indication guidelines of adjuvant chemotherapy have shifted substantially. In the 1980s, chemotherapy was given on the basis of nodal- and menopausal status. At present, the decision to administrate chemotherapy is based on a combined evaluation of tumour stage, tumour grade and menopausal status in order to pursue a 10% disease-free survival gain after 10 years [19]. This shift has led to a higher fraction of early stage breast

Table 3  
Perioperative chemotherapy trials

Study	n patients	Median follow-up (months)	TNM	Study design	RFS	OS
Nissen–Meyer The Scandinavian Adjuvant Chemotherapy Study I 1965–1975	1026	205	T1-3, N0-2, M0 T1-2 80%  N0 60%	I: Mast→1×C→RT vs  II: Mast→RT	I 52% (17 years FU)  II 40% <i>P</i> < 0.001	I 36%  II 31% NS
Cancer Research Campaign 2 Trial [18] 1980–1985	2230	48	T1-2, N0-1, M0  T1 28% N0 49%	I: Mast/BCT→1×C±RT & Tam Vs. II: Mast/BCT→±RT & Tam	I ± 67% (4 years FU)  II ± 67%	NS  NS
IBCSG (Trial V) <sup>a</sup> 1981–1985	2628	42	T1-3a, N0-1, M0  N0 51%→(T1 41%)	Ia: N0: Mast→1×CMFL (< 36 h)  Ib: N+: Mast→1×CMFL (< 36 h)  ± vs IIa: N0: Mast  IIb: N+: 5×CMFLP±Tam  IIc: N+: 6×CMFLP±Tam	N0: Ia 77% (3.5 years FU) IIa 73% <i>P</i> = 0.04 N+: Ib 40% IIb 60% IIc 62% <i>P</i> < 0.0001	N0: Ia 90%  IIa 86% NS N+: Ib 69% IIb 74% IIc 80% <i>P</i> = 0.011
Sertoli 1985–1992	600	68	T1-3a, N0-2, M0  T1 53% T2 39% N0 53%	I: Mast/BCT→1×FEC (< 72 h), if N+: 5×FEC & 6×CMF±RT & Tam vs II: Mast/BCT→RT, if N+: 6× FEC and 6× CMF & Tam	I 76% (5.7 years FU)  II 70% <i>P</i> = 0.053	I 88%  II 84% NS
EORTC 10854 1986–1991	2795	132	T1-3, N0-1, M0  T1 30% N0 53%	I: Mast/BCT→1×FAC±RT & Tam vs II: Mast/BCT→±RT & Tam	I 65% (11 years FU)  II 60% <i>P</i> = 0.025	I 74%  II 71% NS

Mast, mastectomy; C, cyclophosphamide; RT, radiotherapy; BCT, breast-conserving therapy; FEC, 5-fluorouracil epirubicin cyclophosphamide; CMF, cyclophosphamide methotrexate 5-fluorouracil; Tam, tamoxifen; CMFL, cyclophosphamide methotrexate 5-fluorouracil leucovorin; CMFLP, cyclophosphamide methotrexate 5-fluorouracil leucovorin prednisone; FAC, 5-fluorouracil doxorubicin cyclophosphamide; RFS, relapse-free survival; OS, overall survival; NS, not significant.

<sup>a</sup> The International (Ludwig) Breast Cancer Study Group (trial V).

cancer patients receiving chemotherapy nowadays compared with two decades ago.

If this trial was to be executed now, the subgroup of patients who would not receive additional systemic therapy would be much smaller. The question therefore is whether patients in which additional systemic therapy is not indicated nowadays (i.e. node-negative patients with small tumours and favourable histological parameters) would benefit from one course of chemotherapy.

Based upon our results, this question is difficult to answer. However, the presented results can be of use in designing future clinical trials.

However, the outcome that one course of chemotherapy as a sole systemic therapy is able to induce a modest, but significant increase in overall survival

and better locoregional control rates in a subset of low-risk breast cancer patients regardless of the tumour stage and menopausal status, is an important finding.

One could advocate on the basis of this finding that all patients with early stage breast cancer should at least receive some form of chemotherapy. Arguments against this policy have always been based on treatment-related toxicities and the long-term risks of developing haematological malignancies after chemotherapy that would not be counterbalanced by the merits of systemic cytotoxic therapy in node-negative breast cancer patients. This group of patients, however, is known to have a 70–80% long-term survival rate after locoregional therapy alone, meaning that 20–30% of these patients will eventually develop distant metastases and subsequently



die of breast cancer. The argument concerning toxicity may be real in a setting where adjuvant chemotherapy consists of prolonged schemes like in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 trial [20]. This trial investigated whether 12 cycles of methotrexate and 5-fluorouracil followed by leucovorin after surgery would yield better results than surgery alone in premenopausal, node-negative, ER-negative patients. In accordance with our results, this trial demonstrated a significant better disease-free survival rates and better locoregional control in favour of the adjuvant chemotherapy group. A comparable study

conducted by Amadori and colleagues [21] using CMF showed similar data.

In the EORTC trial 10854, only one course of an anthracycline-containing chemotherapeutic regimen was given. This type of adjuvant treatment induced a significant improvement in progression-free survival and locoregional control in the overall analysis, as well as overall survival in a large subset of patients without intolerable mortality and morbidity [22]. Therefore, one should be aware of these data when developing a treatment strategy for patients with early stage node-negative breast cancer.

### Appendix. Participating institutions

Country	Principal investigator	Institution
France	J.-P. Julien J.L. Floiras, F. Bachelot T. Delozier Ph. Vennin	Centre Henri Becquerel, Rouen Centre René Huguenin, St Cloud Centre Regional François Baclesse, Caen Centre Oscar Lambret, Lille
Netherlands	C.J.H. van de Velde, M.A. Nooy G. de Keizer P. Bruning C.W. Taat	Leiden University Medical Center, Leiden Maria Hospital, Tilburg Netherlands Cancer Institute, Amsterdam Academic Medical Center, Amsterdam
Republic of South Africa	J.A. van Zyl, A.G. Muller	University of Stellenbosch, Tygerberg Hospital, Tygerberg
Poland	J. Jaskiewicz, J. Jassem J. Dyczka	Medical University of Gdansk, Gdansk Institute of Oncology, Medical Academy of Lodz
Spain	A. Herruzo-Nalda	Hospital Virgen de las Nieves, Granada
Italy	C. Barone	Policlinico A. Gemelli- Università del sacro Cuore, Rome
Austria	M. Dünser	Innsbruck Universitaetsklinik, Innsbruck
Russia	O. Ivanova, V.F. Semiglazov	Petrov Research Institute of Oncology, St Petersburg
Greece	J. Karydas	Hellenic Cancer Institute- Saint Savas Hospital, Athens

### Acknowledgements

This work was supported by a personal grant from the Dutch Cancer Society NKB/KWF.

### References

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. *Lancet* 1998, **352**, 930–942.
2. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. *Cancer Res* 1983, **43**, 1488–1492.
3. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. *Cancer Res* 1979, **39**, 3861–3865.
4. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. *Cancer Res* 1989, **49**, 1996–2001.
5. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. *Cancer Treat Rep* 1979, **63**, 1727–1733.
6. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. *Cancer Res* 1984, **44**, 3643–3653.
7. The Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. *N Engl J Med* 1988, **319**, 677–683.

8. The Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. *N Engl J Med* 1989, **320**, 491–496.
9. Sertoli MR, Bruzzi P, Pronzato P, et al. Randomized cooperative study of perioperative chemotherapy in breast cancer. *J Clin Oncol* 1995, **13**, 2712–2721.
10. Clahsen PC, van de Velde CJH, Julien JP, et al, cooperating investigators. Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. *J Clin Oncol* 1996, **14**, 745–753.
11. EORTC Breast Cancer Cooperative Group. *Manual for Clinical Research in Breast Cancer*. Almere, The Netherlands, Excerpta Medica, 1998 31–34.
12. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. *J Am Stat Assoc* 1958, **53**, 457–481.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. *Cancer Chemother Rep* 1966, **50**, 163–170.
14. Cox DR. Regression models and life-tables. *J R Stat Soc [B]* 1972, **34**, 187–220.
15. Nissen-Meyer R, Host H, Kjellgren K, Malmio K, Mansson B, Norin T. Surgical adjuvant chemotherapy; Results with one short course with cyclophosphamide after mastectomy for breast cancer. *Cancer* 1978, **41**, 2088–2098.
16. Nissen-Meyer R, Host H, Kjellgren K, Mansson B, Norin T. Treatment of node-negative breast cancer patients with short course of chemotherapy immediately after surgery. *NCI Monogr* 1986, **1**, 125–128.
17. Kjellgren K, Nissen-Meyer R, Norin T. Perioperative adjuvant chemotherapy in breast cancer. The Scandinavian adjuvant chemotherapy study 2. *Acta Oncol* 1989, **28**, 899–901.
18. Houghton, J, Baum M, Nissen-Meyer R, Riley D, Hern RA. Is there a role for perioperative adjuvant cytotoxic therapy in the treatment of early breast cancer? *Rec Res Cancer Res* 1989, **115**, 54–61.
19. Goldhirsch A, Glick JH, Gelber RD, Senn H-J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. *J Natl Cancer Inst* 1998, **90**, 1601–1608.
20. Fisher B, Dignam J, Mamounas PE, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: 8-year results from the national surgical adjuvant breast and bowel project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. *J Clin Oncol* 1996, **14**, 1982–1992.
21. Amadori D, Nanni O, Marangolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. *J Clin Oncol* 2000, **18**, 3125–3134.
22. Clahsen PC, van de Velde CJH, Julien J-P, Floiras J-L, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer. *J Clin Oncol* 1994, **12**, 1266–1271.
23. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomised controlled trials: the CONSORT statement. *JAMA* 1996, **276**, 637–639.